MARKET WIREYahoo Finance UK • 16h ago
AEON Biopharma, Inc. (AEON) Seasonal returns chartYahoo Finance UK report covering AEON Biopharma Inc. (Class A) (AEON) market action, institutional positioning, and fundamental catalysts.
Why AEON Stock dropped -6.80% Today — RQD Quant Desk Flash
$0.27 -6.80% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.27
AEON Biopharma Inc. (Class A) (AEON) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $16.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on AEON Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AEON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, AEON Biopharma Inc. (Class A) (NYSE: AEON) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $0.27 (-6.80% 1D, market cap $16.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AEON ranks #345 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AEON compare to MRKR and NEUP in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AEON carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MRKR (Marker Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and NEUP (Neuphoria Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -11.8%, cap $16.5M). Among the 5-stock peer group, AEON leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AEON?
▼
Per AEON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001837607), AEON Biopharma Inc. (Class A) generated $0 in revenue, -$39.2M in net income, and -$17.3M in free cash flow against $5.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.27 (-1.41%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-3.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AEON)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY AEON SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (26% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$0.23+0% Next Q
38
Q2 (-2Q)Grade D$0.23+8.7% Next Q
41
Q3 (-1Q)Grade D$0.25+8% Next Q
43
CurrentGrade D$0.27-6.1% Hist 90D α
46
Trajectory: E (38) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a AEON Turnaround Squeeze
While AEON currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.26) and Max Pain ($0.28) forces dealer call-delta covering toward $1.52.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AEON• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AEON Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AEON Stock dropped -6.80% Today — RQD Quant Desk Flash
AEON Biopharma Inc. (Class A) (AEON) dropped -6.80% to $0.27, trading at 7% of its 52-week range ($0.18 – $1.45). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 7% of its 52-week range ($0.18 – $1.45) with RSI-14 at 52.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.27 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live AEON Headlines & Catalysts
MARKET WIRETradingView • 19h ago
AEON Biopharma, Inc. Estimates – AMEX:AEONTradingView report covering AEON Biopharma Inc. (Class A) (AEON) market action, institutional positioning, and fundamental catalysts.
MARKET WIRE富途牛牛 • 22h ago
AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711富途牛牛 report covering AEON Biopharma Inc. (Class A) (AEON) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com Canada • 1d ago
Form DEF 14A AEON Biopharma For: 26 October By Investing.comInvesting.com Canada report covering AEON Biopharma Inc. (Class A) (AEON) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Stock Splits Calendar for:Yahoo Finance report covering AEON Biopharma Inc. (Class A) (AEON) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
AEON Biopharma Outlines ABP-450 Biosimilar Plan, Targets Q4 2026 INDTradingView report covering AEON Biopharma Inc. (Class A) (AEON) market action, institutional positioning, and fundamental catalysts.
RISK WATCHkalkine.ca • 1d ago
Data, Downgrades and Disruption: Monte Rosa (NASDAQ:GLUE), Foghorn (NASDAQ:FHTX), Integra LifeSciences (NASDAQ:IART) and Six Other Biotech Stockskalkine.ca report covering AEON Biopharma Inc. (Class A) (AEON) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
CELSET Launches SOLTOX, a Korean Botulinum Toxin Type A Brand, for International MarketsYahoo Finance report covering AEON Biopharma Inc. (Class A) (AEON) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AEON)
- ✓Walkthrough of AEON's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AEON // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -71.58%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.29H $0.29L $0.27C $0.27VOL 774.6K
RES: $0.47SUP: $0.23SMA50: $0.26SMA200: $0.67
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AEON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AEON today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AEON. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AEON today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AEON)
Health Care Rank #345 of 1016
⚔️ MRKR vs AEON Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AEON vs. MRKR, NEUP, RADX, KPTI)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, AEON Biopharma Inc. (Class A) (AEON) ranks #345 by composite RQD confidence (46/100, grade D) and #847 by equity capitalization ($16.2M). Within this direct 5-issuer industry benchmark cohort, AEON leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. AEON currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AEON
ACTIVE
AEON Biopharma Inc. (Class A) | D | 46/100 | — | — | -35.0% | -6.80% | $16.2M | Benchmark Subject |
| MRKR Marker Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -2.97% | $16.3M | /mrkr-vs-aeon → |
| NEUP Neuphoria Therapeutics Inc. | E | 31/100 | — | — | -11.8% | -0.33% | $16.5M | /neup-vs-aeon → |
| RADX Radiopharm Theranostics Limited | D | 46/100 | — | — | — | -3.26% | $15.6M | /radx-vs-aeon → |
| KPTI Karyopharm Therapeutics Inc. | E | 29/100 | — | — | -35.0% | -24.76% | $15.0M | /kpti-vs-aeon → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001837607In its most recent audited fiscal period (FY2025, filed 2025-12-31), AEON Biopharma Inc. (Class A) (AEON) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$39.2M, operating cash flow of -$17.3M, and free cash flow of -$17.3M (+14.7% YoY). On the balance sheet, AEON closed FY2025 with $5.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$39.2M | -$17.3M | -$17.3M | $5.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | $42.0M | -$20.3M | -$20.3M | $3.1M | — |
3. AEON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AEON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, AEON Biopharma Inc. (Class A) (NYSE: AEON) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $0.27 (-6.80% 1D, market cap $16.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AEON ranks #345 in composite RQD confidence.
How does AEON compare to MRKR and NEUP in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AEON carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MRKR (Marker Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and NEUP (Neuphoria Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -11.8%, cap $16.5M). Among the 5-stock peer group, AEON leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AEON?
Per AEON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001837607), AEON Biopharma Inc. (Class A) generated $0 in revenue, -$39.2M in net income, and -$17.3M in free cash flow against $5.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AEON trading relative to its 50-day, 200-day, and 52-week technical levels?
AEON last traded at $0.27 (-6.80% on volume of 774,566 shares), positioning the stock +3.85% above its 50-day simple moving average ($0.26) and -59.70% below its 200-day simple moving average ($0.67). Across its 52-week range of $0.18 to $1.45, AEON sits at the 7.1% percentile with a 14-day RSI of 52.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.30).
AEON Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AEON stock moving today?
Why AEON Stock dropped -6.80% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 46/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
AEON — AEON Biopharma Inc. (Class A): What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:50:15Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, AEON carries an RQD Score of 48 with a letter grade of D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are scored as follows:
- Fundamental Cash Engine: 9 / 20 (ROIC -35%; FCF yield 0%). This is the weakest economic signal: the company is not generating returns on capital or free cash flow in the source data.
- Whale 13F Flow: 14 / 20 (institutional accumulation and options positioning). This is a moderate score; the source does not provide holder detail to explain it (see Analyst View & Smart Money Ownership).
- Insider Conviction: 5 / 20 (SEC Form 4 and Congressional PTR cluster flow). This is the lowest pillar score, indicating weak insider conviction signals.
- Macro Regime Fit: 10 / 20 (Beta 1.0; sector sensitivity). A beta of 1.0 means the stock moves in line with the market per the source data, which provides no defensive cushion.
- Forensic Balance Sheet: 10 / 20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). The Piotroski F-Score of 1 out of 9 is a notably weak reading for a financial-quality check.
For a prospective investor evaluating the stock today, the rating frames a cautious setting: the cash-generation and insider pillars are weak, and the forensic balance-sheet score does not offset them. Upside drivers in the data are limited to the moderate whale-flow pillar and the 11.36% price change in the market data; the valuation tradeoff is that the stock trades at $0.29 with a market capitalization of $17.4M and no earnings-based multiples available in the source data. Educational context only, not personalized advice.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-12.8M | $-39.2M | N/A | $-17.3M | $3.0M | N/A |
| FY 2024 | $0.0M | $73.0M | $42.0M | N/A | $-20.3M | $0.0M | N/A |
Per the SEC financials, FY 2025 shows an operating loss of $-12.8M and a net loss of $-39.2M, while FY 2024 shows positive operating income of $73.0M and net income of $42.0M, with free cash flow negative in both years. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 1 out of 9, both per the Roarable RQD rating's forensic pillar. Debt/Equity is 0.5 per the same source, while the financials table lists cash of $3.0M and debt as N/A for FY 2025.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts feed, the headlines are tagged MARKET WIRE with YELLOW light signals and include: a Yahoo Finance UK seasonal returns chart; a TradingView estimates item; a report of an inducement grant under NYSE American LLC Company Guide Section 711; a Form DEF 14A proxy filing for a 26 October meeting; a Yahoo Finance stock-splits calendar entry; and a TradingView item on an ABP-450 biosimilar plan that targets a Q4 2026 IND. The summaries are generic market-coverage descriptions and do not contain substantive detail beyond the headlines. Risk watch items per the feed include the proxy filing and the inducement grant. The Butterfly supply-chain graph reports no proprietary signals.
Open Questions
- What is the source of the $0.0B market-capitalization figure in the profile versus the $17.4M figure in the market data?
- What products or clinical programs generate the company's activity, and what is the status of the ABP-450 biosimilar plan?
- Why is reported debt listed as N/A while Debt/Equity is cited as 0.5 in the forensic pillar?
- What drove the swing from FY 2024 net income of $42.0M to FY 2025 net loss of $-39.2M, given revenue of $0.0M in both periods?
- What are the specific insider, 13F holder, and analyst details underlying the RQD pillar scores?
AEON Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for AEON Biopharma Inc. (Class A) (AEON) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance UK • 16h ago
AEON Biopharma, Inc. (AEON) Seasonal returns chart Yahoo Finance UK report covering AEON Biopharma Inc. (Class A) (AEON) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 19h ago
AEON Biopharma, Inc. Estimates – AMEX:AEON TradingView report covering AEON Biopharma Inc. (Class A) (AEON) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE 富途牛牛 • 22h ago
AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 富途牛牛 report covering AEON Biopharma Inc. (Class A) (AEON) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com Canada • 1d ago
Form DEF 14A AEON Biopharma For: 26 October By Investing.com Investing.com Canada report covering AEON Biopharma Inc. (Class A) (AEON) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Stock Splits Calendar for: Yahoo Finance report covering AEON Biopharma Inc. (Class A) (AEON) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
AEON Biopharma Outlines ABP-450 Biosimilar Plan, Targets Q4 2026 IND TradingView report covering AEON Biopharma Inc. (Class A) (AEON) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH kalkine.ca • 1d ago
Data, Downgrades and Disruption: Monte Rosa (NASDAQ:GLUE), Foghorn (NASDAQ:FHTX), Integra LifeSciences (NASDAQ:IART) and Six Other Biotech Stocks kalkine.ca report covering AEON Biopharma Inc. (Class A) (AEON) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
CELSET Launches SOLTOX, a Korean Botulinum Toxin Type A Brand, for International Markets Yahoo Finance report covering AEON Biopharma Inc. (Class A) (AEON) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
AEON Bull vs. Bear Conversation Board — What's Your Call at $0.27?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AEON 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $0.31 (+6.9%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is AEON (D • RQD 48/100) a Buy at $0.29?
Welcome to the AEON (AEON Biopharma Inc. (Class A)) Roar Pit. Current RQD Composite is 48/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $0.23 (-20.7%)
Spot @ $0.29 Pump the brakes on AEON — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on AEON, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless AEON Biopharma Inc. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $0.36 (+24.1%)
Spot @ $0.29 AEON cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on AEON, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.29 (52-wk range $0.18 - $1.45), any beat on forward guidance forces shorts and underweight funds to chase.